- Home
- ACRV vs MCAH Comparison
ACRV vs MCAH Comparison
Compare ACRV & MCAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRV | MCAH |
|---|---|---|
| Founded | 2018 | 2026 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.0M | 86.5M |
| IPO Year | 2022 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ACRV | MCAH |
|---|---|---|
| Price | $1.69 | $10.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 267.1K | 20.0K |
| Earning Date | 11-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.27 | $9.92 |
| 52 Week High | $3.56 | $11.04 |
Technical Indicators
Market Signals| Indicator | ACRV | MCAH |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 66.58 |
| Support Level | $1.61 | $10.00 |
| Resistance Level | $2.21 | $11.04 |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 15.47 | 100.00 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
About MCAH Mountain Crest Acquisition 6 Corp. Ordinary Shares
Mountain Crest Acquisition 6 Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.